MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What's Behind Corcept's Recent Legal Troubles

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What's Behind NuScale Power's Recent Volatility and Legal Troubles

1 months ago

What Triggered Kyndryl's Recent Stock Plunge and Legal Troubles

1 months ago

What's Behind Paysafe's Latest Legal Headwinds

3 weeks ago

What's Behind the Recent Legal Challenges to Costco's Iconic Rotisserie Chicken

1 months ago

Meta's Legal Trouble May Run Deeper

Meta Platforms (META) faces fresh pressure following back-to-back court losses that spotlighted internal research, raising new questions about the company's practices.

Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility

Levi & Korsinsky LLP is investigating Medpace Holdings (NASDAQ: MEDP) over potential securities claims following a book-to-bill miss. The probe focuses on whether management misrepresented the clinica...

MEDP

Stock News•2 months ago

CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated

Bernstein Liebhard LLP initiated an investigation into possible securities claims against Corcept Therapeutics Incorporated (NASDAQ: CORT) as of February 5, 2026. The law firm is seeking investors who...

CORT

Stock News•3 months ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Corcept Therapeutics (CORT) shares fell 50% on December 31, 2025, following the FDA's issuance of a Complete Response Letter for its Cushing's syndrome treatment, relacorilant. This severe market reac...

CORT